BioSpace News Archive

BioForest

Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York - Aug. 7, 2019

Presentation scheduled for 2:30 pm ET on August 14, 2019

August 7, 2019
·
4 min read
Business

Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results

Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented

August 7, 2019
·
19 min read
Business

Tangen Biosciences Awarded Expanded Second Phase of Contract

Awarded the second phase of a contract to develop a field-deployable Anthrax diagnostic assay and expand the research to an antimicrobial resistance diagnostic assay.

August 7, 2019
·
3 min read
Business

Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Initiation of single, pivotal, 12-week, Phase 3 gMG clinical trial on track for the second half of 2019

August 7, 2019
·
8 min read
Business

Teva Announces CFO Leadership Transition

Teva has initiated a search to identify its next CFO. Mr. McClellan is expected to remain in his role through the announcement of third quarter results to assist with a smooth transition.

August 7, 2019
·
3 min read
Business

Acerus Reports Second Quarter and Year to Date Fiscal 2019 Financial Results

Strengthened balance sheet with US$5 million subordinated secured loan facility in July

August 7, 2019
·
18 min read
Business

Teva Reports Second Quarter 2019 Financial Results

Revenues of $4.3 billion

August 7, 2019
·
41 min read
Drug Development

Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial

Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine

August 7, 2019
·
6 min read
Emerging Trends, Drivers and Challenges in the Seborrheic Keratosis Treatment Market 2019 – 2023 | Technavio

The global seborrheic keratosis treatment market size is poised to reach USD 634 million by 2023, according to a new report by Technavio, progressing at a CAGR of 6% during the forecast period.

August 7, 2019
·
3 min read
Deals

Cambrex (CBM) Alert: Johnson Fistel Investigates Proposed Sale of Cambrex Corporation; Is $60 a Fair Price?

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cambrex Corporation breached their fiduciary duties in connection with the proposed sale of the Company to private equity firm Permira.

August 7, 2019
·
1 min read